PolyBloc Therapeutics is pioneering cancer treatment by targeting polyamine metabolism—an overlooked driver of tumor growth and immune suppression. Backed by decades of research, our compounds deplete polyamines in tumors, reprogramming immune cells to work with existing therapies. Founded by scientists and driven by collaboration, we’re turning molecular insight into immune-powered precision oncology.
About
This is more than a treatment strategy. It’s a paradigm shift in how we think about cancer at the molecular level. And we’re just getting started.
“Most cancers become addicted to certain metabolic pathways to grow and maintain immune privilege inside the human body. Our goal is to therapeutically revoke this privilege by inhibiting polyamine metabolism and exchange. Our polyamine blocking therapy reprograms the tumor microenvironment to allow the patient’s own immune system to recognize and clear their cancer.”
— Otto Phanstiel, PhD, Founder
“Exciting preclinical studies show that adjunct therapy with our polyamine blocking therapy leads to complete tumor remissions in immunotherapy-resistant cancers with a long-lasting anti-tumor immune memory to prevent secondary tumor growth.”
— Susan Gilmour, PhD, Founder
© 2025 PolyBloc Therapeutics, Inc.™